Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11464189 | 0.90 | ACE (0.51) | MAPK1FFAR1HTTGAAL3MBTL1 | |
| SCHEMBL15745228 | 0.86 | NPC1 (0.56) | FFAR1RAB9ALMNAALDH1A1NPC1 | |
| SCHEMBL8895881 | 0.84 | CYP2C19 (0.66) | MAPK1FFAR1HTTGAARAB9A | |
| SCHEMBL13870189 | 0.83 | MAPT (0.58) | L3MBTL1RAB9ACYP1A2CYP2C19ALDH1A1 | |
| Acetic Acid Methyl Ester SCHEMBL23070551 | 0.82 | CYP2C19 (0.53) | MAPK1FFAR1HTTGAAL3MBTL1 | |
| SCHEMBL5410393 | 0.81 | GAA (0.61) | HTTGAARAB9ACYP1A2LMNA | |
| SCHEMBL10953947 | 0.81 | ALDH1A1 (0.46) | MAPK1FFAR1HTTGAACYP1A2 | |
| SCHEMBL3256326 | 0.81 | NPC1 (0.62) | HTTGAAL3MBTL1RAB9ACYP2C19 | |
| SCHEMBL11265645 | 0.81 | ALDH1A1 (0.61) | MAPK1GAARAB9ACYP1A2CYP2C19 | |
| SCHEMBL9069764 | 0.81 | CYP2C19 (0.57) | MAPK1FFAR1HTTGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116478132-A | 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors | 锐新医药公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116478131-A | 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors | 锐新医药公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-110523541-B | Alkyl thioether ether ethyl hydroximic acid medicament and preparation method and application thereof | 中南大学 | 2021-09-28 | — | — | CN | disclosed |
| US-20210276023-A1 | ALKYL THIOETHER ETHYL HYDROXAMIC ACID BENEFICIATION REAGENT AND PREPARATION METHOD AND APPLICATION THEREOF | CENTRAL SOUTH UNIVERSITY (CN) | 2021-09-09 | — | — | US | disclosed |
| CN-106588720-B | Sulfidomethyl amphyl preparation method and application based on dual catalyst system | 中国科学院宁波材料技术与工程研究所 | 2019-06-11 | — | — | CN | disclosed |
| CN-106588720-A | Dual catalytic system based sulfur methyl phenol derivative preparation method and application | 中国科学院宁波材料技术与工程研究所 | 2017-04-26 | — | — | CN | disclosed |
| EP-1849796-B1 | ANTI-PENICILLIN RESISTANT PNEUMOCOCCI AGENT AND NOVEL 16-MEMBERED RING MACROLIDE DERIVATIVE | MICROBIAL CHEM RES FOUND (JP) | 2014-11-05 | — | — | EP | disclosed |
| US-8507453-B2 | Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8507453-B2 | Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8420698-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1408946-A4 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-1408946-A2 | HISTONE DEACETYLASE INHIBITORS | Circagen Pharmaceutical (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030125306-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | CIRCAGEN PHARMACEUTICAL, A MARYLAND CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-6495719-B2 | FOR USE IN THERAPY OF CANCER, HEMATOLOGICAL DISORDERS, SUCH AS HEMATOPOIESIS, AND GENETIC RELATED METABOLIC DISORDERS, SUCH AS, CYSTIC FIBROSIS AND ADRENOLEUKODYSTROPHY | CIRCAGEN PHARMACEUTICAL | 2002-12-17 | — | — | US | disclosed |
| US-20020143196-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2002-10-03 | — | — | US | disclosed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | disclosed |
| WO-2002076941-A2 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-3988375-A | HERBICIDES | MONSANTO COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | ZFX, HDAC5, ZNF277 | MAPK1 3331/4885FFAR1 1640/4885HTT 2997/4885 |
| US-20020143052-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | MAPK1 3264/4885FFAR1 3522/4885HTT 1868/4885 |
| US-20030125306-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | MAPK1 3264/4885FFAR1 3522/4885HTT 1868/4885 |
| US-20020143196-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC5 | MAPK1 3260/4885FFAR1 3679/4885HTT 2627/4885 |
| US-20020143037-A1 | Histone deacetylase inhibitors | HDAC1, HDAC9, HDAC11 | MAPK1 3365/4885FFAR1 3282/4885HTT 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.